SK4382001A3 - Mglur5 antagonists for the treatment of pain and anxiety - Google Patents

Mglur5 antagonists for the treatment of pain and anxiety Download PDF

Info

Publication number: SK4382001A3
Authority: SK; Slovakia
Prior art keywords: antagonist; mglur; pain; mglur5; treatment
Prior art date: 1998-10-02

Application number

SK438-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Hans Allgeier

Nicholas David Cosford

Peter Josef Flor

Fabrizio Gasparini

Conrad Gentsch

Stephen D Hess

Edwin Carl Johnson

Rainer Kuhn

Mark Tricklebank

Laszlo Urban

Mark Andrew Varney

Gonul Velicelebi

Katharine Walker

Original Assignee

Novartis Ag

Sibia Neurosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-02

Filing date

1999-09-30

Publication date

2001-08-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK4382001(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-10-02 Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en

1999-09-30 Application filed by Novartis Ag, Sibia Neurosciences Inc filed Critical Novartis Ag

2001-08-06 Publication of SK4382001A3 publication Critical patent/SK4382001A3/sk

Links

239000005557 antagonist Substances 0.000 title claims abstract description 58
208000002193 Pain Diseases 0.000 title claims abstract description 33
238000011282 treatment Methods 0.000 title claims abstract description 31
208000019901 Anxiety disease Diseases 0.000 title claims abstract description 18
230000036506 anxiety Effects 0.000 title claims abstract description 18
101150087728 Grm5 gene Proteins 0.000 title 1
108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims abstract description 52
102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims abstract description 52
102000016193 Metabotropic glutamate receptors Human genes 0.000 claims abstract description 37
108010010914 Metabotropic glutamate receptors Proteins 0.000 claims abstract description 37
229940124807 mGLUR antagonist Drugs 0.000 claims abstract description 26
230000002093 peripheral effect Effects 0.000 claims abstract description 15
230000003993 interaction Effects 0.000 claims abstract description 13
230000000202 analgesic effect Effects 0.000 claims abstract description 11
238000000034 method Methods 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 15
210000003169 central nervous system Anatomy 0.000 claims description 13
102000005962 receptors Human genes 0.000 claims description 13
108020003175 receptors Proteins 0.000 claims description 13
206010065390 Inflammatory pain Diseases 0.000 claims description 8
208000004296 neuralgia Diseases 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
208000021722 neuropathic pain Diseases 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 6
230000008499 blood brain barrier function Effects 0.000 claims description 3
210000001218 blood-brain barrier Anatomy 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 2
150000001875 compounds Chemical class 0.000 description 25
241000700159 Rattus Species 0.000 description 14
MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 10
208000004454 Hyperalgesia Diseases 0.000 description 10
229910052739 hydrogen Inorganic materials 0.000 description 9
239000001257 hydrogen Substances 0.000 description 9
230000000694 effects Effects 0.000 description 8
210000000278 spinal cord Anatomy 0.000 description 8
238000012360 testing method Methods 0.000 description 8
-1 cyano, ethynyl Chemical group 0.000 description 7
230000004064 dysfunction Effects 0.000 description 6
150000002431 hydrogen Chemical class 0.000 description 6
230000003040 nociceptive effect Effects 0.000 description 6
HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 5
208000035154 Hyperesthesia Diseases 0.000 description 5
239000003826 tablet Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000000556 agonist Substances 0.000 description 4
239000011575 calcium Substances 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 description 4
239000000243 solution Substances 0.000 description 4
108091006146 Channels Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
230000003070 anti-hyperalgesia Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
125000002768 hydroxyalkyl group Chemical group 0.000 description 3
230000000917 hyperalgesic effect Effects 0.000 description 3
230000002631 hypothermal effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000007306 turnover Effects 0.000 description 3
DDOQBQRIEWHWBT-VKHMYHEASA-N (2S)-2-amino-4-phosphonobutanoic acid Chemical compound OC(=O)[C@@H](N)CCP(O)(O)=O DDOQBQRIEWHWBT-VKHMYHEASA-N 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
GQSLKBHGURRQLG-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(F)C=CC=2)=N1 GQSLKBHGURRQLG-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
208000000094 Chronic Pain Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
238000011795 OF1 mouse Methods 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
125000004663 dialkyl amino group Chemical group 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
238000011552 rat model Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
230000011273 social behavior Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
230000005477 standard model Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
QFKXUDHGSXTPAU-UHFFFAOYSA-N 2-methyl-6-(2-pyridin-3-ylethenyl)pyridine Chemical compound CC1=CC=CC(C=CC=2C=NC=CC=2)=N1 QFKXUDHGSXTPAU-UHFFFAOYSA-N 0.000 description 1
KYJSGWVPWUBKGL-UHFFFAOYSA-N 2-methyl-6-(2-pyridin-3-ylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=NC=CC=2)=N1 KYJSGWVPWUBKGL-UHFFFAOYSA-N 0.000 description 1
NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 1
OONJJBQNBKMFFT-UHFFFAOYSA-N 2-methyl-6-[2-(2,3,5-trichlorophenyl)ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C(=C(Cl)C=C(Cl)C=2)Cl)=N1 OONJJBQNBKMFFT-UHFFFAOYSA-N 0.000 description 1
ANUFAWHRSIJTHW-UHFFFAOYSA-N 2-methylheptanedioic acid Chemical compound OC(=O)C(C)CCCCC(O)=O ANUFAWHRSIJTHW-UHFFFAOYSA-N 0.000 description 1
GINVUTIGCMRSDL-VOTSOKGWSA-N 3-[2-[(e)-2-(3,5-dichlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1\C=C\C1=CC(Cl)=CC(Cl)=C1 GINVUTIGCMRSDL-VOTSOKGWSA-N 0.000 description 1
ODIHLEYTPVYAPY-UHFFFAOYSA-N 3-[2-fluoro-4-[[3-[2-methyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methylamino]phenyl]propanoic acid Chemical compound CC1=CC(OCCCS(C)(=O)=O)=CC=C1C1=CC=CC(CNC=2C=C(F)C(CCC(O)=O)=CC=2)=C1 ODIHLEYTPVYAPY-UHFFFAOYSA-N 0.000 description 1
VTMJKPGFERYGJF-ZETCQYMHSA-N 4-[(s)-amino(carboxy)methyl]benzoic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(C(O)=O)C=C1 VTMJKPGFERYGJF-ZETCQYMHSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010004663 Biliary colic Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000001387 Causalgia Diseases 0.000 description 1
208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229920004011 Macrolon® Polymers 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 1
102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 1
102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 1
102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
101001032838 Rattus norvegicus Metabotropic glutamate receptor 5 Proteins 0.000 description 1
206010038419 Renal colic Diseases 0.000 description 1
206010039670 Sciatic nerve injury Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000004760 Tenosynovitis Diseases 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
206010053552 allodynia Diseases 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000003461 brachial plexus Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
LOCPVWIREQIGNQ-UHFFFAOYSA-N chembl88553 Chemical compound CC1=CC=C(O)C(N=NC=2C=CC=CC=2)=N1 LOCPVWIREQIGNQ-UHFFFAOYSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960004782 chlordiazepoxide Drugs 0.000 description 1
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
231100000895 deafness Toxicity 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
239000003825 glutamate receptor antagonist Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000013291 male lister hooded rat Methods 0.000 description 1
210000005171 mammalian brain Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 1
108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 1
108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 1
108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000003572 second messenger assay Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
SISOFUCTXZKSOQ-ZHACJKMWSA-N sib-1893 Chemical compound CC1=CC=CC(\C=C\C=2C=CC=CC=2)=N1 SISOFUCTXZKSOQ-ZHACJKMWSA-N 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
206010044652 trigeminal neuralgia Diseases 0.000 description 1
238000004804 winding Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)

SK438-2001A 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety SK4382001A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9821503.1A GB9821503D0 (en)	1998-10-02	1998-10-02	Organic compounds
US22081398A	1998-12-23	1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en)	1998-10-02	1999-09-30	Mglur5 antagonists for the treatment of pain and anxiety

Publications (1)

Publication Number	Publication Date
SK4382001A3 true SK4382001A3 (en)	2001-08-06

Family

ID=26314451

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK438-2001A SK4382001A3 (en)	1998-10-02	1999-09-30	Mglur5 antagonists for the treatment of pain and anxiety

Country Status (21)

Country	Link
EP (1)	EP1117403B1 (pl)
JP (1)	JP2002526408A (pl)
KR (1)	KR20010088832A (pl)
CN (1)	CN1187048C (pl)
AT (1)	ATE255894T1 (pl)
AU (1)	AU765644B2 (pl)
BR (1)	BR9914215A (pl)
CA (1)	CA2345137A1 (pl)
DE (1)	DE69913548T2 (pl)
DK (1)	DK1117403T3 (pl)
ES (1)	ES2213389T3 (pl)
HU (1)	HUP0200553A3 (pl)
ID (1)	ID29095A (pl)
IL (2)	IL142047A0 (pl)
NO (1)	NO20011440L (pl)
NZ (1)	NZ510743A (pl)
PL (1)	PL202906B1 (pl)
PT (1)	PT1117403E (pl)
RU (1)	RU2232017C2 (pl)
SK (1)	SK4382001A3 (pl)
WO (1)	WO2000020001A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0005700D0 (en) *	2000-03-09	2000-05-03	Glaxo Group Ltd	Therapy
ATE297734T1 (de)	2000-12-22	2005-07-15	Hoffmann La Roche	Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten
GB0128996D0 (en)	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
SE0303418D0 (sv) *	2003-12-17	2003-12-17	Astrazeneca Ab	New use 1
SE0303419D0 (sv) *	2003-12-17	2003-12-17	Astrazeneca Ab	New use 11
FR2883180B1 (fr) *	2005-03-18	2007-05-25	Pierre Fabre Medicament Sa	Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en)	2005-12-08	2006-01-18	Novartis Ag	Organic compounds
DE102005062985A1 (de) *	2005-12-28	2007-07-05	Grünenthal GmbH	Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
DK2083811T3 (en)	2006-11-22	2017-01-30	Clinical Res Ass Llc	PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) *	2009-12-17	2013-11-19	Hoffmann-La Roche Inc	Ethynyl compounds useful for treatment of CNS disorders
CN102762572A (zh)	2010-02-01	2012-10-31	诺瓦提斯公司	作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en)	2010-02-02	2014-10-15	Novartis AG	Cyclohexyl amide derivatives as crf receptor antagonists
US20130058915A1 (en)	2010-03-02	2013-03-07	Children's Medica Center Corporation	Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en)	2010-05-28	2011-12-01	Xenoport, Inc.	Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en)	2010-07-15	2012-01-19	Xenoport, Inc.	Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en)	2010-10-21	2012-04-26	Massachusetts Institute Of Technology	Methods of treating seizure disorders
UY34094A (es)	2011-05-27	2013-01-03	Novartis Ag	Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2557183A1 (de)	2011-08-12	2013-02-13	Siemens Aktiengesellschaft	Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
WO2013164790A1 (en)	2012-05-03	2013-11-07	Novartis Ag	L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
AU2016273751B2 (en)	2015-06-03	2020-04-02	F. Hoffmann-La Roche Ag	Ethynyl derivatives
KR20200035035A (ko)	2017-07-31	2020-04-01	노파르티스 아게	코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
EP3459939A1 (en)	2017-09-26	2019-03-27	Pragma Therapeutics	Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) *	2018-05-29	2019-10-01	서울대학교산학협력단	통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2056983T3 (es) *	1988-03-21	1994-10-16	Boehringer Ingelheim Pharma	Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
TW544448B (en) *	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives

1999
- 1999-09-30 ID IDW20010730A patent/ID29095A/id unknown
- 1999-09-30 WO PCT/EP1999/007239 patent/WO2000020001A1/en not_active Ceased
- 1999-09-30 AT AT99948905T patent/ATE255894T1/de active
- 1999-09-30 PL PL346876A patent/PL202906B1/pl not_active IP Right Cessation
- 1999-09-30 IL IL14204799A patent/IL142047A0/xx active IP Right Grant
- 1999-09-30 CN CNB998117110A patent/CN1187048C/zh not_active Expired - Fee Related
- 1999-09-30 SK SK438-2001A patent/SK4382001A3/sk unknown
- 1999-09-30 PT PT99948905T patent/PT1117403E/pt unknown
- 1999-09-30 EP EP99948905A patent/EP1117403B1/en not_active Revoked
- 1999-09-30 BR BR9914215-5A patent/BR9914215A/pt not_active Application Discontinuation
- 1999-09-30 HU HU0200553A patent/HUP0200553A3/hu unknown
- 1999-09-30 JP JP2000573360A patent/JP2002526408A/ja active Pending
- 1999-09-30 CA CA002345137A patent/CA2345137A1/en not_active Abandoned
- 1999-09-30 ES ES99948905T patent/ES2213389T3/es not_active Expired - Lifetime
- 1999-09-30 NZ NZ510743A patent/NZ510743A/en unknown
- 1999-09-30 DK DK99948905T patent/DK1117403T3/da active
- 1999-09-30 KR KR1020017004152A patent/KR20010088832A/ko not_active Ceased
- 1999-09-30 RU RU2001111868/14A patent/RU2232017C2/ru not_active IP Right Cessation
- 1999-09-30 DE DE69913548T patent/DE69913548T2/de not_active Revoked
- 1999-09-30 AU AU61984/99A patent/AU765644B2/en not_active Ceased
2001
- 2001-03-15 IL IL142047A patent/IL142047A/en not_active IP Right Cessation
- 2001-03-21 NO NO20011440A patent/NO20011440L/no unknown

Also Published As

Publication number	Publication date
CN1321087A (zh)	2001-11-07
DE69913548D1 (de)	2004-01-22
BR9914215A (pt)	2001-07-03
NO20011440L (no)	2001-05-15
EP1117403B1 (en)	2003-12-10
HUP0200553A3 (en)	2002-11-28
AU6198499A (en)	2000-04-26
NZ510743A (en)	2003-10-31
KR20010088832A (ko)	2001-09-28
ES2213389T3 (es)	2004-08-16
EP1117403A1 (en)	2001-07-25
CA2345137A1 (en)	2000-04-13
JP2002526408A (ja)	2002-08-20
PL346876A1 (en)	2002-03-11
DE69913548T2 (de)	2004-09-23
IL142047A (en)	2007-09-20
IL142047A0 (en)	2002-03-10
HUP0200553A2 (hu)	2002-07-29
AU765644B2 (en)	2003-09-25
NO20011440D0 (no)	2001-03-21
ID29095A (id)	2001-07-26
PL202906B1 (pl)	2009-08-31
PT1117403E (pt)	2004-04-30
DK1117403T3 (da)	2004-04-13
RU2232017C2 (ru)	2004-07-10
WO2000020001A1 (en)	2000-04-13
CN1187048C (zh)	2005-02-02
ATE255894T1 (de)	2003-12-15

Publication	Publication Date	Title
AU765644B2 (en)	2003-09-25	mGluR5 antagonists for the treatment of pain and anxiety
CA2336822C (en)	2009-11-17	Method of treatment and pharmaceutical composition
SK88897A3 (en)	1998-02-04	Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
KR20170003527A (ko)	2017-01-09	경구 투여용 펜토산 폴리설페이트 염의 조성물
US20010056084A1 (en)	2001-12-27	MGluR5 antagonists for the treatment of pain and anxiety
WO2009043834A1 (en)	2009-04-09	Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound
JP2009504737A (ja)	2009-02-05	脈管疾患の治療又は予防のためのｐａｒ−１／ｐａｒ−４阻害剤の使用
Lynch III et al.	2005	ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model
JP2002526408A5 (pl)	2006-11-24
US20070265279A1 (en)	2007-11-15	Use of mGluR5 antagonists for the treatment of pruritic conditions
JP2007529556A (ja)	2007-10-25	認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
US8455548B2 (en)	2013-06-04	Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
PT1003494E (pt)	2007-06-06	( d ) -metadona, um analgésico não opióide.
CZ298398A3 (cs)	1999-06-16	Farmaceutický přípravek
Kohara et al.	2007	Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models
PT1799199E (pt)	2012-07-03	Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica
US20130137725A1 (en)	2013-05-30	Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
SALVATORE	2009	THERESA M. WILLIAMS', CHRISTOPHER S. BURGEY¹ and
CA2772354A1 (en)	2011-03-10	Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists